What Happened
Donna Monticone, a nurse at the Yale Reproductive Endocrinology and Infertility Clinic in Orange, Connecticut, removed fentanyl from vials used to anesthetize patients during fertility procedures, self-injected the drug, and refilled the vials with sterile saline before returning them to stock.
Monticone's responsibilities included ordering and inventorying the clinic's narcotics, giving her both the access and the authority to manage the supply. She began stealing fentanyl in June 2020, initially injecting herself at the clinic and later taking vials home, refilling them with saline there, and reintroducing them into the stock available for surgical use. Investigators found that approximately 75 percent of the fentanyl given to patients at the clinic from June to October 2020 was adulterated with saline — some vials diluted, some containing no drug at all.
Monticone pleaded guilty to tampering with a consumer product and was sentenced to three years of supervised release, four weekends of incarceration, and three months of home confinement. She surrendered her nursing license, and affected patients subsequently sued. Numerous patients reported physical pain during their procedures.
What Went Wrong
This case illustrates how a single individual who controls both inventory and administration can corrupt the entire supply chain of a small procedural setting. Control failures included:
- The nurse responsible for ordering and inventorying narcotics also had unsupervised access to the vials, with no independent reconciliation of orders against use.
- Returned vials were not inspected for seal or content integrity, so saline-filled vials circulated into the anesthesia stock for months.
- Inventory counts could not detect the theft because the tampered vials remained present and countable.
- No patient-outcome monitoring connected reports of pain during procedures to the possibility of adulterated medication.
How It Could Have Been Prevented
- Separate the duties of ordering, receiving, inventorying, and administering controlled substances so no single person controls the full chain.
- Require second-person verification whenever vials are removed from and returned to procedural stock, with seal and content inspection.
- Reconcile orders, receipts, and administration records on a routine schedule, escalating any unexplained gap.
- Investigate patient reports of inadequate anesthesia promptly as a potential product-integrity or diversion indicator.
- Apply peer-comparison analytics to drug use in small procedural settings, flagging out-of-pattern consumption.
- Conduct periodic unannounced physical counts comparing vial presence, weight, or content against the perpetual record.
Related Guidance
- Anesthesia & OR Drug Diversion: Prevention Strategies — Anesthesia & OR diversion prevention guidance for procedural and perioperative settings.
- Tough Issues — High-risk scenarios with annotated SQL, including substitution and inventory-integrity analysis.
- 15 Red Flags of Drug Diversion — Behavioral and transactional indicators including inventory irregularities and patient complaints.
- Hospital Diversion Prevention Checklist — Hospital self-assessment, 8 sections 63 items, including inventory and administration controls.
- Employee Screening & Fitness for Duty — DEA screening requirements (21 C.F.R. §1301.90) and pre-employment vetting for staff with controlled substance access.
- Patient Notification After Drug Diversion — When and how to notify potentially exposed patients and offer bloodborne pathogen testing.